PremiumThe FlyVor Bio downgraded to Neutral from Outperform at Wedbush Vor Bio downgraded to Hold from Buy at JonesResearch Vor Biopharma trading resumes PremiumCompany AnnouncementsVor Bio Advances in Clinical Trials and Secures Funding Optimistic Buy Rating for Vor Biopharma Amidst Economic Challenges and Promising Clinical Potential Optimistic Buy Rating for Vor Biopharma Amid Promising Clinical Developments and Stable Financial Position PremiumThe FlyVor Bio presents research on patients participating in CGT trials Vor Biopharma Approves Stock Option Repricing Strategy Vor Bio files to sell 125.71M shares of common stock for holders 
